Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration

Bisphosphonates (BPs) have recently been shown to have direct anti-tumor properties. Systemic treatment with BPs can have multiple adverse effects such as osteonecrosis of the jaw and BP induced bone fracturing and spine instability. While benefits of systemic BP treatments may outweigh risks, local...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Bone Oncol
Main Authors: Nooh, Anas, Zhang, Yu Ling, Sato, Daisuke, Rosenzweig, Derek H., Tabariès, Sébastien, Siegel, Peter, Barralet, Jake E., Weber, Michael H.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5262502/
https://ncbi.nlm.nih.gov/pubmed/28138422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2017.01.001
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares